Benign prostatic hyperplasia (BPH) is a chronic condition associated with lower urinary tract symptoms (LUTS) such as urinary hesitancy, weak stream and incomplete emptying. Abnormal urodynamic findings can also be features of BPH. Current management of BPH is focused on alleviating symptoms.1
This section offers useful information about pathophysiology, prevalence, impact, diagnosis and treatment options for BPH. Use the menu to go directly to the topics that interest you most.
 |
The Pathophysiology of BPH |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. Barry MJ, Goodson JD. Approach to benign prostatic hyperplasia. In: Goroll AH, May LA, Mulley AG Jr, eds. Primary Care Medicine. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:794-798.
